This company listing is no longer active
NUGX Stock Overview
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
NuGenerex Immuno-Oncology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$0.30 |
52 Week Low | US$0.000001 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 9,900.00% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
NUGX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -3.7% | -1.6% |
1Y | 9,900.0% | 17.2% | 30.8% |
Return vs Industry: NUGX exceeded the US Pharmaceuticals industry which returned -1.7% over the past year.
Return vs Market: NUGX exceeded the US Market which returned 4% over the past year.
Price Volatility
NUGX volatility | |
---|---|
NUGX Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NUGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NUGX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | n/a | Joe Moscato | www.generex.com/nugenerex-family-of-companies |
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer.
NuGenerex Immuno-Oncology, Inc. Fundamentals Summary
NUGX fundamental statistics | |
---|---|
Market cap | US$10.12k |
Earnings (TTM) | -US$6.29m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NUGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NUGX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$6.29m |
Earnings | -US$6.29m |
Last Reported Earnings
Apr 30, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did NUGX perform over the long term?
See historical performance and comparison